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Abstract
Background
Previous studies in mice and humans have implicated the lipoprotein receptor SCARB1 in
association with atherosclerosis and lipid levels. In the current study, we sought to examine
association of SCARB1 missense single nucleotide polymorphism (SNP) rs4238001 with
incident coronary heart disease (CHD).

Methods and Results
Genotypes for rs4238001 were imputed for 2,319 White, 1,570 African American, and
1,292 Hispanic-American MESA participants using the 1,000 Genomes reference set. Cox
proportional hazards models were used to determine association of rs4238001 with incident
CHD, with adjustments for age, sex, study site, principal components of ancestry, body
mass index, diabetes status, serum creatinine, lipid levels, hypertension status, education
and smoking exposure. Meta-analysis across race/ethnic groups within MESA showed statistically significant association of the T allele with higher risk of CHD under a consistent and
formally adjudicated definition of CHD events in this contemporary cohort study (hazard
ratio [HR]=1.49, 95% CI [1.04, 2.14], P = 0.028). Analyses combining MESA with additional
population-based cohorts expanded our samples in Whites (total n = 11,957 with 871 CHD
events) and African Americans (total n = 5,962 with 355 CHD events) and confirmed an increased risk of CHD overall (HR of 1.19 with 95% CI [1.04, 1.37], P = 0.013), in African
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Americans (HR of 1.49 with 95% CI [1.07, 2.06], P = 0.019), in males (HR of 1.29 with 95%
CI [1.08, 1.54], P = 4.91x10-3) and in White males (HR of 1.24 with 95% CI [1.03, 1.51], P =
0.026).

Conclusion
SCARB1 missense rs4238001 is statistically significantly associated with incident CHD
across a large population of multiple race/ethnic groups.

Introduction
Deficiency of the scavenger receptor class B type I (SR-BI) in mice is significantly associated
with abnormal lipoprotein composition (especially LDL-cholesterol [LDL-C] and HDL-cholesterol [HDL-C]) and accelerated atherosclerosis in the background of ApoE-/- or ldlr-/-, among
other phenotypic changes [1–5]. Rigotti et al. [6] showed that plasma total cholesterol levels
were significantly elevated in SR-BI knockout (KO) mice as compared with wild-type mice.
Using fast protein liquid chromatography, these investigators observed that the HDL profiles
were very different, with a heterogeneous peak and enrichment of apoE. Similar differences in
the IDL/LDL profiles were also observed in the SR-BI KO mice. Braun et al. [7] subsequently
reported the association of SR-BI deficiency in mice with early onset atherosclerotic disease.
Many of these phenotypic changes have now been identified in humans who are carriers of
certain SCARB1 single nucleotide polymorphisms (SNPs). In one of the earlier observations,
Acton et al. [8] reported that the missense rs4238001 variant, which is a nonsynonymous coding SNP in exon 1 that encodes an amino acid change at the second position from glycine to
serine (p.Gly2Ser), was significantly associated with higher levels of HDL-C and lower levels of
LDL-C in males, with no association observed in females. More recently, West et al. [9] showed
that SR-BI protein expression was an independent predictor of HDL-C levels in subjects with
hyperalphalipoproteinemia. Furthermore, these investigators showed that body mass index
(BMI) and rs4238001 were independent predictors of SR-BI protein levels. Of note, subjects
who were carriers of the risk T allele for rs4238001 had significantly lower SR-BI protein levels
as compared with carriers of the referent allele. Moreover, in vitro approaches showed that the
rs4238001 variant was significantly associated with increased degradation of SR-BI protein and
reduced function as measured by decreased specific cholesteryl ester uptake from HDL [9].
Our previous genetic analyses of SCARB1 variants in MESA participants [10,11] did not examine the common functional polymorphism rs4238001, as it was neither genotyped in the cohort, nor available in our imputation of SNPs from the HapMap I+II reference panel [12].
Subsequently, the 1,000 Genomes project [13] characterized an even broader set of SNPs than
previously available in the HapMap, making it possible for us to carry out, for the first time,
this hypothesis driven association analysis of the primary candidate SCARB1 SNP rs4238001
with incident CHD in MESA participants. We focus the current investigation on the single
SNP rs4238001, as it was the only common SCARB1 missense variant reported in the Exome
Variant Server (http://evs.gs.washington.edu/EVS/) with minor allele frequency (MAF) > 5%.
In addition to primary genetic association analysis, we also examined the role of traditional
risk factors, such as lipids (HDL-C and LDL-C), and non-traditional risk factors, such as lipoprotein subfractions and inflammatory biomarkers, in the causal pathway of rs4238001 with
CHD outcomes.
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While performing analyses within MESA allowed for uniformity in definitions of CHD and
extended regression modeling using the rich set of additional risk factors available within the
cohort, we recognized the importance of examining the association of rs4238001 with CHD in
a larger set of population-based samples. Therefore, we expanded our main association analysis
to incorporate participants from three additional cohorts. Combining these additional cohorts
with participants from MESA, our investigation represented a total of n = 11,957 Whites (with
n = 871 CHD cases) and n = 5,962 African Americans (with n = 355 CHD cases), and
n = 1,255 Hispanics (with n = 39 CHD cases) in the fully adjusted regression analyses. The larger sample size was particularly important in providing improved power to examine the effects
of rs4238001 in race/ethnic- and sex-specific stratified analyses. We emphasize, however, that
the primary aim of the current study is to examine the evidence of association between
rs4238001 and CHD overall, with race/ethnic- and sex-specific analyses constituting secondary
analyses for the current effort. Our study represents a careful and detailed characterization of
clinically relevant cardiovascular endpoints (e.g. CHD) for a missense SNP with previously
demonstrated functional effects on SR-BI degradation and cholesteryl ester uptake [9].

Methods
Ethics statement
All MESA participants gave written informed consent, including consent to participate in genetic studies. The MESA study was approved by the Institutional Review Boards of the National Heart Lung and Blood Institute and all participating institutions, including Wake Forest
University, Columbia University, Johns Hopkins University, the University of Minnesota,
Northwestern University, the University of California—Los Angeles, the Cedars-Sinai Medical
Center and the University of Virginia. All methodology was compliant with the principles set
forth in the Declaration of Helsinki.

Study Design
The Multi-Ethnic Study of Atherosclerosis (MESA) is a longitudinal study of subclinical atherosclerosis (SCA) and risk factors that predict progression to clinically overt cardiovascular
disease (CVD) or progression of the subclinical disease [14]. The first clinic visits occurred in
2000–2002 in 6,814 participants recruited from six field centers across the United States, and
all participants were free of CVD at the baseline exam. Approximately 38% of the recruited
participants were White, 28% African American, 22% Hispanic, and 12% Asian, predominantly of Chinese descent. MESA was approved by the IRB at all participating sites, and all participants gave informed consent.

Phenotyping of MESA participants
MESA participants had detailed medical histories (including medication and smoking history)
and underwent examinations for anthropometry, blood pressure and vascular imaging. Fasting
blood samples were taken for DNA, lipids and inflammatory biomarkers. Cardiovascular
events were adjudicated by a MESA committee, in a process that has already been published
[15].

Genotyping and imputation
Participants recruited for the original MESA cohort (n = 6,814) were genotyped in 2009 using
the Affymetrix Human SNP array 6.0. Genotype quality control for these data has been described previously [11]. Because the SCARB1 SNP rs4238001 was not genotyped in MESA, we
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imputed the genotypes for MESA participants using the available genome-wide genotypes. IMPUTE version 2.2.2 [16] was used to perform imputation for the MESA SHARe participants
using the 1,000 Genomes cosmopolitan Phase 1 v3 reference panel [13] and the SNP was imputed with good quality (observed-expected variance ratio > 0.8) in MESA Whites, African
Americans and Hispanics. MESA Chinese were not included in the current investigation because the allele frequency in this group did not pass our inclusion threshold of MAF > 0.05.
We further validated the quality of imputation by comparison with genotypes obtained by direct exome sequencing through the NHLBI Exome Sequencing Project for a subset of 399
MESA participants (251 White and 148 African American) [17]. Among these participants, we
observed 97.1% and 99.3% concordance in Whites and African Americans, respectively, comparing best guess genotypes obtained by imputation with those obtained directly by
exome sequencing.

Genetic association analysis in MESA
We began with stratified analyses within each race/ethnic group in MESA. We performed Cox
proportional hazards analysis of incident CHD with respect to rs4238001 genotype under an
additive 1 df genetic dosage model for the risk allele T. We began with a basic regression model
(Model 1) that included adjustment for age, sex, study site and principal components of ancestry, an extended model that added adjustment for major coronary risk factors (Model 2) including body mass index (BMI), diabetes status, serum creatinine, LDL-C, HDL-C,
hypertension status, education, and smoking exposure (ever smoke and current smoke), a
model that extended Model 2 with adjustment for statin use (Model 3), and a model that added
to Model 2 adjustment for HDL and LDL particle number and size from NMR spectroscopy
(Model 4). These regression analyses were further stratified by sex for each race/ethnic group.
Following race/ethnic stratified analyses, we performed fixed effect meta-analysis to combine results across all three race/ethnic groups in METAL [18]. We designated the pooled analyses (of males and females) under Models 1 and 2 as our primary analyses. We report all Pvalues <0.05 from regression analyses for primary analyses. Additional regression Models 3
and 4, and sex-stratified analyses are designated as secondary analyses. We report results from
secondary analyses in order to interpret the results from primary analyses.

Validation cohorts
We sought validation of the observed associations for the rs4238001 SNP through expanded
analysis incorporating independent cohorts spanning both White and African American populations, including the Atherosclerosis Risk in Communities Study (ARIC), the Framingham
Heart Study (FHS) and the Jackson Heart Study (JHS) for whom GWAS genotyping were
available to allow imputation of the rs4238001 SNP. Additional details are described in S1 Supporting Information.

Results
Characteristics of the MESA study samples
The MESA participants included in our genetic association analyses included 2,319 Whites,
1,570 African Americans, and 1,292 Hispanics, roughly evenly distributed between males and
females. The median age of participants in each ethnic group ranged from 61–63 years, with an
interquartile range (IQR) of 53–71 years of age. Body mass index values were highest in African
Americans (median [IQR] of 29.4 [26.1, 33.6] kg/m2) and lowest among Whites (27.0 [24.2,
30.3] kg/m2). Triglyceride levels were notably lower in African Americans (90 [66, 123] mg/dl)
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Table 1. Characteristics of MESA participants across three ethnic groups.
White

African
American

Hispanic

Pvalue†
—-

Participant characteristics*
No. subjects

2319

1570

1292

Women

1208 (52.1)

841 (53.6)

655 (50.7)

0.308

Age, years

63 [54, 71]

63 [53, 70]

61 [53, 69]

<0.001

BMI, kg/m2

27.0 [24.2,
30.3]

29.4 [26.1, 33.6]

28.6 [26.0,
31.8]

<0.001

Education: completed high school
Education: completed technical degree, associate degree, bachelor's degree or
higher

2199 (95.1)

1369 (87.9)

684 (52.9)

<0.001

1410 (61.0)

749 (48.1)

273 (21.1)

<0.001

Triglycerides, mg/dL

114 [77, 164]

90 [66, 123]

136 [96, 192]

<0.001

HDL-C, mg/dL

50 [41, 61]

50 [41, 60]

45 [39, 54]

<0.001

LDL-C, mg/dL

115 [95, 136]

115 [95, 136]

119 [98, 139]

Serum creatinine, mg/dL

0.90 [0.80,
1.10]

1.00 [0.90, 1.10]

0.90 [0.80,
1.00]

<0.001

Diabetes (yes/no)

130 (5.6)

272 (17.4)

228 (17.7)

<0.001

Hypertension (yes/no)

899 (38.8)

932 (59.4)

550 (42.6)

<0.001

Ever smoke (yes/no)

1287 (55.7)

851 (54.7)

593 (45.9)

<0.001

Current smoke (yes/no)

263 (11.3)

290 (18.5)

175 (13.5)

<0.001

Lipid medication (yes/no)

421 (18.2)

246 (15.7)

177 (13.7)

0.002

Coronary heart disease—All

142 (6.1)

73 (4.6)

60 (4.6)

0.063

Coronary heart disease—Hard

77 (3.3)

46 (2.9)

40 (3.1)

0.785

Myocardial infarction

63 (2.7)

24 (1.5)

34 (2.6)

0.031

Follow-up time (years)

7.6 [7.4, 7.8]

7.5 [7.0, 7.7]

7.6 [7.1, 7.8]

0.003

Clinical events

<0.001

Data are presented as N (%) for binary measures or median [IQR] for continuous measure.
*Summary statistics are reported for the subset of individuals with data available for at least one of the clinical events.
†P-values are presented for statistical signiﬁcance of the difference in values across race/ethnic groups according to a likelihood ratio test with 2 degrees
of freedom.
doi:10.1371/journal.pone.0125497.t001

compared with Hispanics (136 [96, 192] mg/dl), while HDL-C, LDL-C, and serum creatinine
measures were qualitatively similar across ethnic groups. At baseline, Whites demonstrated
lower prevalence of diabetes (5.6%) than both African Americans (17.4%) and Hispanics
(17.7%). Hypertension was also less frequent in Whites (38.8%) compared to African Americans (59.4%) and Hispanics (42.6%). Rates of current smoking were <20% in each of the three
ethnic groups. Lipid medication use was also <20% in each of the three ethnic groups included
in the current investigation (Table 1). Clinical events were assessed after a median 7.6 years of
follow-up by a MESA adjudication committee that applied a uniform definition of events to all
participants that included incident MI, definite angina, probable angina (if followed by coronary artery bypass grafting or percutaneous coronary intervention), resuscitated cardiac arrest,
or coronary heart disease death. At this point in the study, the cumulative incidence of probable or confirmed CHD events (CHD-All) was 6.1%, 4.6% and 4.6% in Whites, African
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Americans and Hispanics, respectively, while the cumulative incidence of confirmed CHD
events (CHD-Hard) was 3.3%, 2.9% and 3.1%, respectively (Table 1). Rates of CHD events
were consistently higher in males (4.7%, 4.1% and 4.6%) than females (2.1%, 1.9%, 1.7%) in
Whites, African Americans and Hispanics.

SCARB1 rs4238001 SNP and CHD in MESA
Since we had previously reported that rs4238001 was an independent predictor of SR-BI protein and that this variant was significantly associated with accelerated SR-BI protein degradation and reduced cholesteryl ester uptake, the next logical step was to assess its association with
hard clinical CVD endpoints. Thus, the current investigation begins with a known testable hypothesis rather than a discovery effort as often seen in GWAS and related genetic screening approaches. Therefore, we did not employ any correction for multiple comparisons, and used the
nominal threshold of P = 0.05 for statistical significance. The primary hypothesis for the current investigation is that rs4238001 genotype is associated with CHD in the general population.
Stratified analyses by sex and race/ethnicity are secondary to this primary hypothesis.
In meta-analysis, we observed a statistically significant increase in the risk of CHD-Hard for
the risk T allele (S1 Table, hazard ratio [HR] of 1.49, 95% CI [1.04, 2.14], P = 0.028) under a regression model that includes adjustment for major coronary risk factors (Model 2). In stratified
analyses by race/ethnic group, we observed statistically significant association of the risk T allele in African Americans (S2 Table, Model 2 HR of 2.15 (95% CI [1.06, 4.35], P = 0.033). We
did not observe significant association of CHD-Hard with the risk T allele in Whites, nor in
Hispanics (S2 Table). We reiterate, however, that the risk T allele showed a significant association with increased risk of CHD events in meta-analysis across race/ethnic groups and the increase in risk with the T allele was observed consistently across all three race/ethnic groups
(heterogeneity P-value = 0.42). Sensitivity analyses showed our finding were robust to multiple
models of adjustment (S1 Table and S2 Table, Fig 1).
We examined evidence of association for rs4238001 with CHD in meta-analysis that combined sex-specific results across the three race/ethnic groups. In males, we observed statistically
significant association with CHD-Hard (S1 Table, Model 2 HR = 1.76, 95% CI [1.14, 2.71],
P = 0.011). We observed hazard ratios of the same direction and similar magnitude in both
males and females (heterogeneity P-value = 0.54). We did not observe any statistically significant association at the nominal level (α = 0.05) in race/ethnic-specific analysis of males. In African American females, we observed statistically significant evidence of association with
CHD-Hard (S2 Table, Model 2 HR = 3.59, 95% CI [1.17, 11.07], P = 0.027). This result corresponds to an odds ratio of 3.98 (95% CI [1.18, 13.47], P = 0.026) for increased risk of
CHD-Hard among African American females. We emphasize, however, that sex-stratified results within race/ethnic groups represent relatively fewer CHD cases (S2 Table). In addition,
consideration of multiple regression models and stratified analyses goes beyond the strict evaluation of our primary hypothesis for association of rs4238001 genotype with CHD overall
under a controlled type I error rate of α = 0.05. Accordingly, the statistically significant result
in African American females should be interpreted with caution.

Lipid subfractions and biomarkers
The association of rs4238001 with CHD-Hard was significant even after multiple adjustments
with traditional CVD risk factors including lipids. Therefore, we examined the association of
rs4238001 with lipids and subfractions in the three MESA race/ethnic groups. As shown in Fig
2, combined meta-analysis across race/ethnic groups showed LDL-C levels were higher in carriers of the risk T allele. In race/ethnic specific analysis, LDL-C levels were higher in White
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Fig 1. Effect estimates (log hazard ratio of CHD for rs4238001 effect allele T) and corresponding 95%
confidence intervals shown for Model 1 (basic), Model 2 (extended), Model 3 (Model 2 + lipid
medication) and Model 4 (NMR lipids). Analyses were conducted stratified by race/ethnic group and
combined by meta- analysis, for all participants as well as stratified by sex (males or female).
doi:10.1371/journal.pone.0125497.g001

males, lower in African American males, and not statistically significantly different in Hispanic
male carriers of the risk allele. We did not observe statistically significant association of
rs4238001 with LDL-C levels in females. LDL particle numbers were nominally significantly
higher in White males, lower in African American males and not different in Hispanic
male carriers.
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Fig 2. Summary of estimated genetic additive effects of rs4238001 allele T on LDL-C (mg/dL), LDL particle number (nmol/L) and LDL particle size
(log nm) under a basic regression model (Model 1). Analyses were conducted stratified by race/ethnic group and combined by meta-analysis, for all
participants as well as stratified by sex (males or female).
doi:10.1371/journal.pone.0125497.g002

Overall, we did not observe strong differences in mean HDL-C levels with respect to
rs4238001 genotypes (S3 Table). Using a formal regression model to examine association of
HDL parameters with rs4238001 genotypes, we did not observe statistically significant association with HDL-C levels in male carriers of the risk allele (Fig 3). However, HDL-C levels were
significantly higher in African American female carriers compared to homozygotes for the reference allele. For HDL particle number, we observed statistically significantly lower levels in
African American male carriers of the risk allele. There were no significant differences with
HDL particle size in either sex.
We next examined the association of the risk allele with biomarkers of inflammation and
thrombosis. The results showed that the risk T allele did not significantly affect levels of

PLOS ONE | DOI:10.1371/journal.pone.0125497 May 20, 2015

8 / 16

SCARB1 Missense Variant rs4238001 and Incident CHD

Fig 3. Summary of genetic additive effects of rs4238001 allele T on HDL-C (log mg/dL), HDL particle number (nmol/L) and HDL particle size (log
nm) under a basic model (Model 1). Analyses were conducted stratified by race/ethnic group and combined by meta-analysis, for all participants as well as
stratified by sex (males or female).
doi:10.1371/journal.pone.0125497.g003

interleukin-6, eSelectin1, sICAM1, PAI-1, hsCRP or homocysteine, regardless of race or sex
stratification (S4 Table).

Expanded analysis with additional Whites and African Americans
Building on the results from MESA, we proceeded to examine associations with CHD events in
independent cohorts of Whites from the Atherosclerosis Risk in Communities (ARIC) Study
and the Framingham Heart Study (FHS) and African Americans from ARIC and the Jackson
Heart Study (JHS) (S5 Table). To obtain a clean set of events in the validation cohorts, we applied a strict definition of CHD events to include MI or CHD death.
Combining MESA with additional population-based cohorts expanded our samples in
Whites (total n = 11,957 with 871 CHD events across three cohorts [MESA, ARIC and FHS])
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and African Americans (total n = 5,962 with 355 CHD events across three cohorts [MESA,
ARIC and JHS]). Incorporating MESA Hispanics, the current investigation included a total of
n = 19,174 participants with 1265 CHD cases. In meta-analysis across race/ethnic groups, we
confirmed an increased risk of CHD overall (Table 2, HR of 1.19 with 95% CI [1.04, 1.37],
P = 0.013) and in males (HR of 1.29 with 95% CI [1.08, 1.54], P = 4.91x10-3). We further observed statistically significant evidence of association in race/ethnic specific analysis of African
Americans (HR of 1.49 with 95% CI [1.07, 2.06], P = 0.019) and in White males (HR of 1.24
with 95% CI [1.03, 1.51], P = 0.026). Notably, the observed direction of effect for the risk T allele was consistent across all race/ethnic groups and sex-strata examined in our expanded analyses (Table 2).
Combining MESA with additional population-based cohorts expanded our samples in
Whites (total n = 11,957 with 871 CHD events across three cohorts [MESA, ARIC and FHS])
and African Americans (total n = 5,962 with 355 CHD events across three cohorts [MESA,
ARIC and JHS]). Incorporating MESA Hispanics, the current investigation included a total of
n = 19,174 participants with 1265 CHD cases. In meta-analysis across race/ethnic groups, we
confirmed an increased risk of CHD overall (Table 2, HR of 1.19 with 95% CI [1.04, 1.37],
P = 0.013) and in males (HR of 1.29 with 95% CI [1.08, 1.54], P = 4.91x10-3). We further observed statistically significant evidence of association in race/ethnic specific analysis of African
Americans (HR of 1.49 with 95% CI [1.07, 2.06], P = 0.019) and in White males (HR of 1.24
with 95% CI [1.03, 1.51], P = 0.026). Notably, the observed direction of effect for the risk T allele was consistent across all race/ethnic groups and sex-strata examined in our expanded analyses (Table 2).

Discussion
We completed a genetic association study for the common functional polymorphism
rs4238001 with CHD and MI events in MESA. In analysis that combined data from Whites,
African Americans and Hispanics, we identified significant evidence for the risk T allele as a
factor for CHD-Hard events in MESA participants. When combining evidence across all race/
ethnic groups from MESA, we observed significant evidence of the rs4238001 SNP as a risk factor for CHD-Hard in males, but not in all female groups. The evidence of association was
strongest in African Americans, with consistent direction of risk effect seen in the other
ethnic groups.
As the current investigation was hypothesis driven in testing the effect of a known missense
mutation in a well-established gene of functional significance, we did not carry out formal correction for multiple comparisons. However, we recognize that we have carried out multiple
stratified analyses by sex and race/ethnicity. We emphasize that these stratified analyses are
secondary compared to the primary question of whether or not rs4238001 associates with
CHD overall. Differences observed across strata in the current study may be taken as hypothesis generating, and will require future hypothesis-driven research for follow-up. Another potential source of multiple testing lies in the multiple regression models under consideration.
We emphasize, however, that we have employed only a single model (Model 2) for testing our
primary hypothesis. Additional regression models presented in this work are shown for the
purpose of sensitivity analysis to examine results with adjustment for additional factors of interest. Notably, we did not observe strong qualitative changes in our results with the different
covariate adjustments considered.
In analyses stratified by sex in MESA, the increased risk of CHD in male participants is consistent with well-established observations of higher CHD rates in males [19–20]. In women,
meta-analysis did not show a significant association of rs4238001 with CHD. Interestingly, the

PLOS ONE | DOI:10.1371/journal.pone.0125497 May 20, 2015

10 / 16

PLOS ONE | DOI:10.1371/journal.pone.0125497 May 20, 2015
0.055
0.098

African American

Hispanic

0.053
0.103

African American

Hispanic

0.056
0.094

African American

Hispanic

Meta-analysis

0.105

White

Meta-analysis

0.103

White

Meta-analysis

0.104

MAF†

White

Group

2642 (51)

637 (10)

818 (16)

1187 (25)

2421 (111)

618 (29)

715 (30)

1088 (52)

5063 (162)

1255 (39)

1533 (46)

2275 (77)

N (events)

1.347 (0.649, 2.798)

0.693 (0.104, 4.61)

3.593 (1.166, 11.068)

0.649 (0.212, 1.988)

1.754 (1.135, 2.71)

1.809 (0.73, 4.484)

1.714 (0.64, 4.595)

1.744 (0.982, 3.096)

1.495 (1.044, 2.14)

1.639 (0.756, 3.554)

2.151 (1.064, 4.348)

1.214 (0.739, 1.993)

Hazard Ratio (95% CI)

MESA

0.424

0.704

0.027

0.449

0.011

0.200

0.284

0.058

0.028

0.235

0.033

0.442

P-value

8100 (456)

-

2732 (164)

5368 (292)

6011 (647)

-

1697 (145)

4314 (502)

14111 (1103)

-

4429 (309)

9682 (794)

N (events)

1.087 (0.857, 1.377)

-

1.252 (0.785, 1.997)

1.033 (0.783, 1.361)

1.214 (1.000, 1.474)

-

1.432 (0.768, 2.671)

1.192 (0.973, 1.462)

1.145 (0.986, 1.328)

-

1.339 (0.923, 1.943)

1.111 (0.944, 1.307)

Hazard Ratio (95% CI)

Additional cohorts*

0.496

-

0.343

0.819

0.051

-

0.259

0.092

0.076

-

0.125

0.205

P-value

10742 (507)

-

3550 (180)

6555 (317)

8432 (758)

-

2412 (175)

5402 (554)

19174 (1265)

-

5962 (355)

11957 (871)

N (events)

1.108 (0.885, 1.389)

-

1.462 (0.95, 2.251)

1.006 (0.769, 1.316)

1.289 (1.079, 1.541)

-

1.508 (0.89, 2.555)

1.244 (1.026, 1.507)

1.191 (1.039, 1.366)

-

1.485 (1.068, 2.063)

1.126 (0.97, 1.307)

Hazard Ratio (95% CI)

0.370

-

0.084

0.966

4.91x10-3

-

0.127

0.026

0.013

-

0.019

0.119

P-value

Combined (MESA + Additional cohorts)

doi:10.1371/journal.pone.0125497.t002

allele, with common allele homozygotes CC as the reference group.

smoking exposure (ever smoke [yes/no] and current smoke [yes/no]). Hazard ratios are presented based on an additive 1 df dosage model for the number of copies of the risk T

Regression analysis results are based on Cox proportional hazards models of CHD for rs4238001 (effect allele T) including the covariates for Model 2: age, sex, principal
components of ancestry, study site (cohort speciﬁc), body mass index (BMI), diabetes status (yes/no), serum creatinine, LDL-C, HDL-C, hypertension status (yes/no), education,

†The frequency of rs4238001 risk T allele is reported for all participants from the contributing cohorts for the stated race/ethnic group.

*Additional cohorts include ARIC and FHS for Whites, and ARIC and JHS for African Americans.

Female

Male

All

rs4238001

Table 2. Association of rs4238001 with CHD events for MESA and combined with participants from additional cohorts in Whites and African Americans.
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association of rs4238001 with LDL-C was similarly stronger in males than in females, suggesting the underlying effects of the rs4238001 variant exhibit similar patterns of sex-specificity for
both LDL-C and CHD. While the association of rs4238001 with CHD remained significant
across multiple regression models with adjustment for traditional risk factors (like HDL-C and
LDL-C) and non-traditional risk factors such as lipoprotein particle number/size and education, we do not rule out the possibility of a role for lipids in the effect of rs4238001 on CHD. Indeed, adjustment for baseline LDL-C cannot reflect the full range of effects that LDL-C may
have on an individual’s cardiovascular risk throughout the course of a lifetime.
Follow-up including an expanded set of Whites from ARIC and FHS and African Americans from ARIC and JHS provided additional support for the association of rs4238001 with
CHD overall, in African Americans, as well as in sex-stratified analyses of males and White
males, in particular. The statistical significance within these subgroups reflects, in part, the
greater power we had to observe effects in groups with greater sample sizes, higher rates of
CHD, and/or higher frequency of the rs4238001 risk allele (S6 Table).
The estimated effects observed in the cohorts added at the stage of expanded analyses were
generally attenuated compared to those seen in MESA (Table 2). The observed differences in
effects may reflect in part the Winner’s curse, a phenomenon in which larger effect sizes are
seen in discovery cohorts compared to those found in subsequent validation efforts [21]. In addition, we emphasize that MESA has some important differences compared to the other cohorts, including being the only contemporary cohort and having its own internally consistent
definitions of hard CHD events that could not be carried over to the expanded analyses. Recognizing that the minor allele frequency for the SNP ranges from 5–10% across race/ethnic
groups, and that event counts for carriers of the T allele are small for individual cohorts (S7
Table), we caution against systematic interpretation of stratified and cohort-specific results.
We further emphasize that the rs4238001 allele T conferred increased risk of CHD in all subgroups examined for our current analyses, and failure to achieve statistical significance within
a particular subgroup does not imply a lack of association within that group.
In analyses stratified by race/ethnic group in MESA, the association of rs4238001 with incident CHD was significant in African Americans across the multiple regression models. The effect estimate was positive in all models, which suggests the increased risk for incident CHD in
this race/ethnic group was also independent of traditional risk factors. Hurley et al. [22] demonstrated that some traditional risk factors, such as HDL, are not strong predictors of CHD in
African Americans. Further study of rs4238001 in relation to CHD outcomes may offer the opportunity to identify novel risk factors of particular relevance to African Americans. This area
of research may serve to address the higher rate of cardiovascular mortality in minority populations, especially for premature cardiovascular death (<65 years of age) in African Americans
[23].
To date there have been few studies that examined the association of SCARB1 SNPs with
prevalent or incident CVD. We recently reported the association of the intronic SCARB1 SNP
rs10846744 with subclinical atherosclerosis and incident CVD [11], and a nearby SNP was also
reported among those reaching the FDR threshold of 5% in a recent large-scale GWAS of CHD
from the CARDIOGRAMplusC4D consortium [24]. The SNP rs10846744 lies more than 35 kb
downstream from rs4238001, and the two SCARB1 SNPs exhibit very little linkage disequilibrium (R-squared of 0.002, 0.030 and 0.002 for 1,000 Genomes Phase 1 v3 EUR, AFR and AMR
samples, respectively). Recently, Rejeb et al. [25] reported association of three SCARB1 SNPs,
including rs4238001, as significantly associated with coronary stenosis in patients with diabetes
and metabolic syndrome. Vergeer et al. [26] has also previously identified a rare nonsynonymous mutation within SCARB1 that reduced SR-BI function but did not reduce protein levels.
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These investigators did not observe an increased risk for atherosclerosis in family members carrying the risk allele for the missense mutation.
Although we and others have previously examined genetic associations with SCARB1 SNPs,
few studies have reported directly on the association of the common missense rs4238001 with
cardiovascular risk factors and outcomes. One reason for the relative absence of reports on
rs4238001 is that this particular SNP lies in a GC-rich region of the genome, making it challenging to design high-throughput genotyping chips typically used for large-scale genetic studies. For example, rs4238001 was selected for inclusion on the CARe IBC chip, but did not pass
design. In the NHLBI Exome Sequencing Project [27], rs4238001 did not get adequate read
depth to be selected for inclusion on the ExomeChip, even though it is a common variant with
MAF > 0.05 in Whites, African Americans and Hispanics. For these reasons, few large-scale
genetic consortia have reported results for this SNP. The public release of the 1,000 Genomes
Phase 1 data has created the opportunity to impute such variants, and we are optimistic this resource will facilitate more wide-spread inclusion of rs4238001 in future genetic studies.
We previously reported that macrophages stably expressing rs4238001 showed enhanced
degradation of SR-BI protein and significantly reduced selective cholesteryl-ester uptake from
HDL [9]. The deleterious effect of this missense mutation on SR-BI protein levels and function
has also been predicted based on bioinformatic approaches [27]. The Exome Variant Server
(http://evs.gs.washington.edu/EVS/) produced by the NHLBI Exome Sequencing Project reports for rs4238001 a PolyPhen prediction of ‘probably damaging’ and a Genomic Evolutionary Rate Profiling (GERP) conservation score of 3.22, demonstrating conservation in this
region of the protein. Bioinformatic analysis using HaploReg [28] revealed a number of nuclear
proteins predicted to bind to rs4238001 including POL2, OCT2, POUI2F2, AP2ALPHA,
AP2GAMMA, MXI1, RAD21, CCNT2, E2F6, and TAF1.
While we observed the rs4238001 T allele associated with increased LDL-C and LDL particle
numbers in White males from MESA, the associations with CHD in an expanded set of
n = 5,402 White males were based on regression models that accounted for LDL-C and other
major cardiovascular risk factors. Therefore, our results suggest the rs4238001 SNP exerts independent effects on both LDL-C and CHD, with both effects playing a stronger role in males.
These results suggest the effects of SR-BI on circulating lipoprotein cholesterol content, particle
size and number in humans is not directly causal.
Acton et al. [8] previously reported that male carriers of the rs4238001 risk T allele residing
in Zaragoza, Spain had significantly higher HDL-C levels. In contrast, we did not observe significant effects of the T allele on HDL-C levels in male participants of MESA. This might be attributable to our larger sample size (n = 201 men in the Spanish study) and/or to gene-dietary
interactions between the two populations [29]. Investigators had previously shown that young
adult carriers of the risk T allele had higher LDL-C levels when consuming a diet rich in saturated fats, suggesting an important role of SR-BI in human LDL-C metabolism [30]. It is also
possible that alterations in cellular SR-BI protein expression and function might have more direct causal effects on atherosclerosis that have yet to be identified.
In summary, the common rs4238001 missense SNP in SCARB1 was significantly associated
with incident CHD in MESA participants, particularly men and African Americans. Analyses
that incorporated independent population-based samples from three additional cohorts further
underscored the importance of the association of rs4238001 on males, and White males in particular. Importantly, analyses within MESA that adjusted for traditional and nontraditional
CVD risk factors did not attenuate this association, suggesting other pathways need to be explored to identify the causal one(s). The significant interaction of the rs4238001SNP with body
mass index and the effects this interaction had on LpPLA2 mass and activity in African
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American women offers the possibility that inflammatory pathways might be key mediators in
the causal pathway.
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